California's Youth Smoking and Vaping Rates Decrease in 2021

Oct.18.2022
California's Youth Smoking and Vaping Rates Decrease in 2021
The CHKS report shows a decline in tobacco and e-cigarette use among California students, attributed to T21 law.

According to a report from the California Healthy Kids Survey (CHKS), only 1% of 7th and 9th-grade students, and 2% of 11th-grade students reported smoking in 2021, defined as smoking "one or more days" within 30 days prior to the survey. The data also shows that since 2015, smoking rates have decreased by 50% among 7th-grade students, 75% among 9th-grade students, and 71.4% among 11th-grade students.


Furthermore, the use of e-cigarettes has also dropped. According to a survey, e-cigarette usage peaked in 2015, with 7% of students, 13% of 9th graders, and 14% of 11th graders reporting they had used e-cigarettes in the 30 days prior to the survey. However, in 2021, this rate hit an all-time low, with only 2% of 7th graders, 6% of 9th graders, and 10% of 11th graders reporting current e-cigarette use.


Earlier this year, additional data was released regarding the legal impact of California in 2016, which reported a positive trend. The law raised the legal age for tobacco sales from 18 to 21 (T21). In 2016, California passed a law that raised the age limit for tobacco sales from 18 to 21. The Pacific Research and Evaluation Prevention Research Center conducted a study called "New research investigating the impact of California's minimum age of 21 for tobacco sales.


Data compilation shows that the T21 law has had a positive impact on public health among 7th, 9th, and 11th grade students statewide. The survey results are summarized on News-Medical.


Reduce the prevalence of lifelong use of combustible tobacco and e-cigarettes, as well as the past month's use of combustible tobacco among the entire student population.


Over the past month, there has been an increase in the usage of electronic cigarettes.


Reduce lifetime and past 30-day use of all tobacco and nicotine products among Latinx youth.


Positive public health impacts on other racial and ethnic groups that are distinct.


Title: California's E-cigarette Usage Rates, T21, California Health Children Survey A recent survey in California has revealed significant statistics on the usage of electronic cigarettes, also known as e-cigarettes, in the state. The survey also examined the T21, a law that raises the minimum age for buying tobacco products, including e-cigarettes, to 21. The survey, named California Health Children Survey, reported that 7% of surveyed high school students had used e-cigarettes at least once in the past 30 days. Moreover, 15% of 11th graders reported current usage of e-cigarettes. The survey also showed that T21 has resulted in a decrease in tobacco product usage among youths under 21 years old. There has been a significant drop in the usage of e-cigarettes, with a decrease of 6% in the past 12 months alone. Overall, the survey suggests that e-cigarette usage remains an issue in California, particularly among high school students. However, the implementation of T21 has shown a positive impact in decreasing tobacco usage among younger demographics, including e-cigarettes.


Statement:


This article is compiled from third-party information and is intended for industry discussion and learning purposes.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of its contents. The translation of this article is intended only for industry exchange and research purposes.


Due to limitations in the level of translation, the translated article may not express the same meaning as the original. Please refer to the original article for accuracy.


2FIRSTS maintains complete alignment with the Chinese government regarding any domestic, Hong Kong, Macau, Taiwan, or international statements and positions.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Trump Names Darrell Scott as CDC Tobacco Health Adviser, Citing Tobacco Risks and Harm-Reduction Solutions
Trump Names Darrell Scott as CDC Tobacco Health Adviser, Citing Tobacco Risks and Harm-Reduction Solutions
U.S. President Donald Trump has named Pastor Darrell Scott to serve as an adviser on tobacco health issues on the Centers for Disease Control and Prevention’s Advisory Committee to the Director. Trump said Scott would focus on the burden of tobacco-related disease and help examine ways to protect Americans from dangerous tobacco products while supporting solutions that reduce harm. Scott’s public career has largely centered on faith leadership, community advocacy and politics.
Sep.02
HG Innovation, linked to IMiracle and ELFBAR, wins China patent for 6-methylnicotine salts covering vaping and oral products
HG Innovation, linked to IMiracle and ELFBAR, wins China patent for 6-methylnicotine salts covering vaping and oral products
HG Innovation Limited has been granted a Chinese invention patent covering 6-methylnicotine salt formulations and their use in oral and vaping products. The technology forms salts between 6-methylnicotine and alicyclic carboxylic acids, with granted claims extending to oral products, atomization substrates and electronic atomization devices. Applicant-generated tests reported differences in oxidation stability, in-vitro cytotoxicity and aerosol heavy-metal performance compared with selected benzoate or lactate controls. HG Innovation is directly linked to the broader IMiracle and ELFBAR business network.
Sep.04
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Imperial Brands' acquisition of Swedish Helwit owner Yoik Group AB has highlighted the professional-services firms supporting cross-border oral nicotine M&A. Latham & Watkins and KPMG advised Imperial, while PwC and TM & Partners advised Yoik. KPMG also appeared on Imperial's acquisition of Black Buffalo earlier in 2026, while PwC played an extensive role in KT&G's acquisition of Swedish nicotine-pouch company Another Snus Factory. Imperial's public disclosures put the global modern oral nicotine delivery market at approximately £8.8 billion in retail sales and 23.5 billion pouches in 2024
Sep.20
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
At the 2026 New Approaches Summit in New York, former FDA Center for Tobacco Products Director Mitch Zeller called for the tobacco harm reduction debate to shift from the traditional “end game” toward defining a desired “end state.” He also highlighted unresolved concerns around dual use, argued that biomarkers of exposure may be more meaningful than cigarettes-per-day in assessing risk reduction, and said nicotine misperceptions remain a major barrier to public health progress.
Sep.25
Kumulus Vape2026 H1 Revenue Falls 8.3% but Profit Rises 24% as B2B Weakens and Consumer Channels Grow
Kumulus Vape2026 H1 Revenue Falls 8.3% but Profit Rises 24% as B2B Weakens and Consumer Channels Grow
French vaping company Kumulus Vape reported first-half 2026 revenue of €25.5 million, down 8.3% year over year, as its core B2B distribution business fell 11% to €21.6 million. B2C and store-network revenue rose 5.6% and 17.8%, respectively. Commercial margin increased to 26.3% from 21.7%, while net profit rose 24.1% to €0.8 million. The company attributed the profitability improvement to catalog optimization, logistics restructuring and the ramp-up of Labster, its in-house production unit for proprietary brands.
Market
Sep.17 by 2Firsts Perspectives
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
At the 2026 New Approaches Summit in New York, FDA Center for Tobacco Products Director Bret Koplow said the PMTA pathway is “predicated on tobacco harm reduction.” He outlined four CTP priorities: youth prevention, helping adults quit or switch to lower-risk products, improving relative-risk communication, and reducing unauthorized products. Koplow also addressed flavored e-cigarettes, public risk perceptions, industry credibility and efforts to make PMTA reviews more efficient and predictable.
Sep.26